About orgenesis inc - ORGS
Orgenesis, Inc. is a biotechnology company, which engages in the development, manufacturing, and provision of technologies and services in the cell and gene therapy industry. It operates through the following segments: Octomera and Therapies. The Octomera segment refers to the point-of-care services. The Therapies segment is involved in therapeutic development operations. The company was founded by Sarah Ferber on June 5, 2008 and is headquartered in Germantown, MD.
ORGS At a Glance
Orgenesis, Inc.
20271 Goldenrod Lane
Germantown, Maryland 20876
| Phone | 1-480-659-6404 | Revenue | 1.04M | |
| Industry | Packaged Software | Net Income | -48,165,000.00 | |
| Sector | Technology Services | 2024 Sales Growth | 95.283% | |
| Fiscal Year-end | 12 / 2025 | Employees | 77 | |
| View SEC Filings |
ORGS Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 7.689 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.066 |
| Enterprise Value to Sales | 24.636 |
| Total Debt to Enterprise Value | 0.716 |
ORGS Efficiency
| Revenue/Employee | 13,441.558 |
| Income Per Employee | -625,519.481 |
| Receivables Turnover | 25.875 |
| Total Asset Turnover | 0.13 |
ORGS Liquidity
| Current Ratio | 0.028 |
| Quick Ratio | 0.028 |
| Cash Ratio | 0.026 |
ORGS Profitability
| Gross Margin | -224.638 |
| Operating Margin | -2,513.527 |
| Pretax Margin | -4,726.184 |
| Net Margin | -4,653.623 |
| Return on Assets | -605.735 |
| Return on Equity | N/A |
| Return on Total Capital | 250.312 |
| Return on Invested Capital | N/A |
ORGS Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | -94.891 |
| Total Debt to Total Assets | 1,351.517 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | -50.837 |